A pharmaceutical company is designing a Phase III randomized controlled trial (RCT) to evaluate the efficacy of a new antihypertensive drug in Indian adults aged 40–65 years with stage 2 hypertension. The trial protocol specifies a 1:1 allocation ratio, but the biostatistician raises concern about baseline imbalance in a key prognostic variable (left ventricular hypertrophy, LVH) between the two arms after randomization. What is the most appropriate next step to minimize this risk in future recruitment?

Explanation

## Addressing Baseline Imbalance in RCT Design **Key Point:** Stratified randomization is a prospective design strategy that ensures balanced distribution of known prognostic variables across treatment arms *before* randomization occurs. ### Why Stratified Randomization is the Best Next Step 1. **Prospective control of confounding**: By stratifying on LVH status (present vs. absent), randomization is performed *within* each stratum independently, guaranteeing equal numbers in each arm for this prognostic factor. 2. **Reduces variance**: This design increases statistical power by reducing unexplained variance attributable to the stratification variable. 3. **Maintains randomization integrity**: Unlike post-hoc adjustment, stratification is built into the protocol *a priori*, preserving the intent-to-treat principle. ### Comparison of Approaches | Approach | Timing | Effectiveness | Preserves Randomization? | |----------|--------|---------------|-------------------------| | **Stratified randomization** | Prospective (during design) | Excellent | Yes | | Increased sample size | Prospective | Moderate (dilutes imbalance by chance) | Yes | | Post-hoc adjustment | Retrospective (after data lock) | Acceptable but weaker | Compromised | | Quasi-experimental design | Design change | Introduces selection bias | No | **High-Yield:** Stratified randomization is the **gold standard** for managing known prognostic imbalances in RCT design. It is especially valuable in smaller trials (N < 500) where simple randomization may fail to balance prognostic factors. **Clinical Pearl:** In Indian hypertension trials, LVH is a critical prognostic variable because it predicts cardiovascular outcomes independently. Balancing it across arms strengthens the trial's ability to detect true drug effects. ### Implementation in This Trial The trial protocol should specify: - Stratification variable: LVH status (present/absent, confirmed by echocardiography at baseline screening) - Randomization method: Permuted block randomization within each stratum - Block size: Typically 4 or 6 (to maintain concealment) **Mnemonic:** **STRAT** = **S**tratify on **T**he **R**isk **A**nd **T**hen randomize.